Using cells devoid of Ras proteins as tools for drug discovery

Molecular Carcinogenesis

Volumn 48, Issue 11, 2009, Pages 1038-1047

  Urosevic, Jelena ^a   Sum, Eleanor Y M ^a,b   Moneo, Victoria ^a   Drosten, Matthias ^a   Dhawahir, Alma ^a   Becerra, Mercedes ^a   Carnero, Amancio ^a   Barbacid, Mariano ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Raf Mek Erk kinases; Rasless cells; Selective inhibitors; Signaling pathways

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 7 HYDROXYSTAUROSPORINE; ALPHA [AMINO(4 AMINOPHENYLTHIO)METHYLENE] 2 (TRIFLUOROMETHYL)PHENYLACETONITRILE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; ARCTIGENIN; B RAF KINASE; CISPLATIN; FLAVOPIRIDOL; GENISTEIN; IMATINIB; KENPAULLONE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; PACLITAXEL; PROTEIN KINASE B INHIBITOR; PROTEIN P53; RAPAMYCIN; RAS PROTEIN; ROSCOVITINE; STAUROSPORINE; SU 1498; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVATION; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; DNA PRIMERS; DRUG DISCOVERY; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; PROTEIN KINASE INHIBITORS; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 70350455128     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20555     Document Type: Article

References (50)

1. Malumbres M, Barbacid M. RAS oncogenes: The first 30 years. Nat Rev Cancer 2003;3:459-465.
2. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22. (Pubitemid 37328883)
3. Karnoub AE, Weinberg RA. Ras oncogenes: Split personalities. Nat Rev Mol Cell Biol 2008;9:517-531.
4. Repasky GA, Chenette EJ, Der CJ. Renewing the conspiracy theory debate: Does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol 2004;14:639-647.
5. Suzuki A, Nakano T, Mak TW, Sasaki T. Portrait of PTEN: Messages from mutant mice. Cancer Sci 2008;99:209-213. (Pubitemid 351232668)
6. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-3310.
7. Schreck R, Rapp UR. Raf kinases: Oncogenesis and drug discovery. Int J Cancer 2006;119:2261-2271. (Pubitemid 44546944)
8. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109. (Pubitemid 39331023)
9. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
10. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008;27:5511-5526.
11. Brocard J, Warot X, Wendling O, et al. Spatio-temporally controlled site-specific somatic mutagenesis in the mouse. Proc Natl Acad Sci USA 1997;94:14559-14563. (Pubitemid 28041413)
12. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003;4:111-120. (Pubitemid 37040827)
13. Esteban LM, Vicario-Abejon C, Fernandez-Salguero P, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol 2001;21:1444-1452. (Pubitemid 32156364)
14. Rodriguez-Viciana P, Warne PH, Khwaja A, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997;89:457-467. (Pubitemid 27220890)
15. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007;6:541-555.
16. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004;5:875-885. (Pubitemid 39486539)
17. Bottorff D, Stang S, Agellon S, Stone JC. RAS signalling is abnormal in a c-raf1 MEK1 double mutant. Mol Cell Biol 1995;15:5113-5122.
18. Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2008;68:5524-5528.
19. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252.
20. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005;15:11-18. (Pubitemid 41653958)
21. Lackey K, Cory M, Davis R, et al. The discovery of potent cRaf1 kinase inhibitors. Bioorg Med Chem Lett 2000;10:223-226. (Pubitemid 30105376)
22. Horiuchi KY, Wang Y, Diamond SL, Ma H. Microarrays for the functional analysis of the chemical-kinase interactome. J Biomol Screen 2006;11:48-56. (Pubitemid 43255781)
23. Chin PC, Liu L, Morrison BE, et al. The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J Neurochem 2004;90:595-608. (Pubitemid 38989390)
24. Chen HM, Wang L, D'Mello SR. Inhibition of ATF-3 expression by B-Raf mediates the neuroprotective action of GW5074. J Neurochem 2008;105:1300-1312. (Pubitemid 351590789)
25. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity toMEKinhibition. Nature 2006;439:358-362.
26. Duncia JV, Santella JB III, Higley CA, et al. MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett 1998;8:2839-2844.
27. Atkins CM, Selcher JC, Petraitis JJ, Trzaskos JM, Sweatt JD. The MAPK cascade is required for mammalian associative learning. Nat Neurosci 1998;1:602-609. (Pubitemid 128406370)
28. Selcher JC, Atkins CM, Trzaskos JM, Paylor R, Sweatt JD. A necessity for MAP kinase activation in mammalian spatial learning. Learn Mem 1999;6:478-490. (Pubitemid 29503844)
29. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995;92:7686-7689.
30. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-18632. (Pubitemid 28334795)
31. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-947. (Pubitemid 39626217)
32. Okajima E, Thorgeirsson UP. Different regulation of vascular endothelial growth factor expression by the ERK and p38 kinase pathways in v-ras, v-raf, and v-myc transformed cells. Biochem Biophys Res Commun 2000;270:108-111. (Pubitemid 30440400)
33. Thimmaiah KN, Easton JB, Germain GS, et al. Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J Biol Chem 2005;280:31924-31935.
34. Cho MK, Jang YP, Kim YC, Kim SG. Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: The role in TNF-alpha inhibition. Int Immunopharmacol 2004;4:1419-1429.
35. Hausott B, Greger H, Marian B. Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells. J Cancer Res Clin Oncol 2003;129:569-576. (Pubitemid 37363596)
36. Eich E, Pertz H, Kaloga M, et al. (-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase. J Med Chem 1996;39:86-95. (Pubitemid 26025539)
37. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001;98:13681-13686.
38. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105. (Pubitemid 30781561)
39. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-456.
40. Toledo F, Wall GM. Regulating the p53 pathway: In vitro hypotheses in vivo veritas. Nat Rev Cancer 2006;6:909-923.
41. Wang D, Boerner SA, Winkler JD, LoRusso PM. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 2007;1773:1248-1255. (Pubitemid 47161034)
42. Zhang YG, Du Q, Fang WG, Jin ML, Tian XX. Tyrphostin AG1478 suppresses proliferation and invasion of human breast cancer cells. Int J Oncol 2008;33:595-602.
43. Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003;55:401-423. (Pubitemid 37013211)
44. Kubota T. Gastrointestinal stromal tumor (GIST) and imatinib. Int J Clin Oncol 2006;11:184-189. (Pubitemid 44087116)
45. Singletary K, Ellington A. Genistein suppresses proliferation and MET oncogene expression and induces EGR-1 tumor suppressor expression in immortalized human breast epithelial cells. Anticancer Res 2006;26:1039-1048.
46. Lakshman M, Xu L, Ananthanarayanan V, et al. Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 2008;68:2024-2032.
47. Katanasaka Y, Ida T, Asai T, Maeda N, Oku N. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. Int J Pharm 2008;360:219-224.
48. Boguslawski G, McGlynn PW, Harvey KA, Kovala AT. SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of phosphorylated ERK kinases and inhibits their activity in vivo and in vitro. J Biol Chem 2004;279:5716-5724. (Pubitemid 38220601)
49. Raught B, Gingras AC, Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad SciUSA2001;98:7037-7044.
50. Gray N, Detivaud L, Doerig C, Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem 1999;6:859-875. (Pubitemid 29422199)